Identification and validation of an immune-related programmed cell death signature for predicting prognosis and immunotherapy in large-scale multicenter cohorts for lung adenocarcinoma
The IRPCDS serves as a robust and promising tool for enhancing clinical outcomes and precision medicine for individual LUAD patients. By integrating PCD signatures, this approach provides valuable insights into the prognostic landscape of LUAD, paving the way for more effective immunotherapeutic strategies.
Authors
- Zaiqi Ma
- Wenbo Ji (ORCID: https://orcid.org/0000-0003-4764-2193)
- Chengcheng Fu (ORCID: https://orcid.org/0000-0001-8623-848X)
- Jie Chen (ORCID: https://orcid.org/0000-0002-3509-2975)
- Zhetao Li (ORCID: https://orcid.org/0000-0002-4324-0608)
Institutions
- Qingdao University (CN)
- Affiliated Hospital of Qingdao University (CN)
Publication Details
- Journal
- Translational Cancer Research
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/tcr-2025-1015
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00